NsGene is a Denmark and US-based biotechnology company located in the greater Copenhagen area and in Providence, RI. Founded in 1999 in Denmark, the company more recently established a US operation in 2011.
NsGene identifies novel neurotrophic proteins with therapeutic effects in the nervous system and develops innovative technologies to target protein therapeutics across the blood-brain-barrier and directly to diseased nerve cells. Focused on primarily neurodegenerative disorders, the Company has a strong pipeline of research and development product candidates. Based on its R&D efforts, NsGene is developing ground breaking therapeutic products for multiple indications with high medical needs including Alzheimer’s disease, Parkinson's disease, deafness, neuropathic pain, epilepsy, cortico-basal degeneration (CBD) and Huntington’s disease.